Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.41 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8170937 | 1.00 | KCNH2 (0.51) | KCNH2AHRCYP1A2PTGS2ALOX5 | |
| SCHEMBL27629497 | 0.82 | KCNH2 (0.53) | KCNH2AHRCYP1A2PTGS2ALOX5 | |
| SCHEMBL13824133 | 0.82 | KCNH2 (0.53) | KCNH2AHRCYP1A2PTGS2ALOX5 | |
| SCHEMBL27610241 | 0.79 | KCNH2 (0.58) | KCNH2AHRCYP1A2PTGS2ALOX5 | |
| SCHEMBL8442224 | 0.78 | NFE2L2 (0.50) | PTGS2ALOX5PTGS1FBP1GRIK1 | |
| SCHEMBL73286 | 0.78 | AHR (0.50) | KCNH2AHRCYP1A2PTGS2ALOX5 | |
| SCHEMBL5704309 | 0.78 | NFE2L2 (0.50) | PTGS2ALOX5PTGS1FBP1GRIK1 | |
| SCHEMBL73285 | 0.78 | AHR (0.50) | KCNH2AHRCYP1A2PTGS2ALOX5 | |
| SCHEMBL9497613 | 0.77 | ALOX5 (0.35) | KCNH2PTGS2ALOX5PTGS1MAOB | |
| SCHEMBL6002839 | 0.77 | HSD17B10 (0.44) | KCNH2AHRCYP1A2PTGS2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| EP-3904366-A1 | END CAPPED NUCLEIC ACID MOLECULES | Novartis AG (CH) | 2021-11-03 | — | — | EP | disclosed |
| CN-112299946-A | Method for synthesizing 1, 2-disubstituted olefin by reacting terminal group olefin with sulfoxide | 沅江华龙催化科技有限公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-112299945-A | Method for synthesizing alkyl olefin by coupling double-bond carbon-hydrogen bond and saturated carbon-hydrogen bond | 沅江华龙催化科技有限公司 | 2021-02-02 | — | — | CN | disclosed |
| US-20200190132-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-06-18 | — | — | US | disclosed |
| US-10676499-B2 | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA | NOVARTIS AG (CH) | 2020-06-09 | — | — | US | disclosed |
| WO-2020027304-A1 | NOVEL CAROTENOID-RELATED DERIVATIVES, AND SALTS, ESTERS, OR AMIDES THEREOF | アスタファーマシューティカルズ株式会社 | 2020-02-06 | — | — | WO | disclosed |
| US-20180002368-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-01-04 | — | — | US | disclosed |
| US-9844540-B2 | Combination therapies for treating cancer | REDHILL BIOPHARMA LTD. (IL) | 2017-12-19 | — | — | US | disclosed |
| US-5877253-A | TERPOLYMERS OF AN AROMATIC MONOMER HAVING AN UNSUBSTITUTED ETHYLENIC GROUP, AN AROMATIC MONOMER HAVING AN ALKYL-SUBSTITUTED ETHYLENIC GROUP, AND AN ACID MONOMER, NEUTRALIZED WITH AMMONIA OR AN AMINE. | HENKEL CORPORATION (US) | 1999-03-02 | — | — | US | disclosed |
| WO-1997014746-A1 | FILM-FORMING COMPOSITIONS | HENKEL CORPORATION (US) | 1997-04-24 | — | — | WO | disclosed |
| WO-1997001602-A1 | METHOD OF PREPARING INORGANIC PIGMENT DISPERSIONS | HENKEL CORPORATION (US) | 1997-01-16 | — | — | WO | disclosed |
| US-5466838-A | Catalytic reaction of olefin with oxygen in the presence of aldehyde | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-11-14 | — | — | US | disclosed |
| EP-0540009-B1 | Process for producing epoxides | SUMITOMO CHEMICAL CO (JP) | 1995-08-30 | — | — | EP | disclosed |
| US-5367087-A | Process for producing epoxide | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1994-11-22 | — | — | US | disclosed |
| EP-0540009-A1 | Process for producing epoxides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-05-05 | — | — | EP | disclosed |
| EP-0350069-B1 | METHOD FOR OXIDIZING UNSATURATED AROMATIC COMPOUNDS | NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) | 1993-03-17 | — | — | EP | disclosed |
| US-4967009-A | REACTING UNSATURATED AROMATIC COMPOUNDS WITH AROMATIC IODOSYL COMPOUNDS TO YIELD AROMATIC ALDEHYDES OR KETONES | NIPPON PETROCHEMICALS CO., LTD. (JP) | 1990-10-30 | — | — | US | disclosed |
| EP-0350069-A2 | Method for oxidizing unsaturated aromatic compounds | NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | RNGTT, NSUN2, NSUN3 | KCNH2 4749/4885AHR 4674/4885CYP1A2 4883/4885 |
| US-20200190132-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | RNGTT, NSUN2, NSUN3 | KCNH2 4749/4885AHR 4674/4885CYP1A2 4883/4885 |
| US-20180002368-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NSUN2, NSUN3, RNGTT | KCNH2 4765/4885AHR 4421/4885CYP1A2 4882/4885 |
| US-10676499-B2 | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA | RNGTT, NSUN3, NSUN2 | KCNH2 4669/4885AHR 4677/4885CYP1A2 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.